Michel Ducreux

Michel Ducreux

Medical Oncologist

Gastrointestinal Oncology

Gustave Roussy

Location France, Villejuif

Linkedin

Dr. Michel Ducreux is a French medical oncologist specializing in gastrointestinal malignancies, with a long-standing academic and clinical career at Gustave Roussy. His expertise includes pancreatic cancer, colorectal cancer, hepatocellular carcinoma, and neuroendocrine tumors. He has extensive leadership experience in clinical research, cooperative oncology groups, and international guideline development.

Current Position

  • Head, GastroIntestinal Oncology Unit
  • Head, Gastro-Intestinal Tumor Board (since April 2020)

Previous Academic & Hospital Appointments

  • Assistant Physician, Gastroenterology Unit, Bicêtre Hospital, Paris (1988–1991)
  • Associate Professor, Gastroenterology Unit, Gustave Roussy (1992–1997)
  • Head of the Gastroenterology Unit, Gustave Roussy (from 1997)
  • Professor of Medical Oncology (since 2005)
  • Executive Medical Director, Gustave Roussy (November 2010 – December 2019)Education
  • MD, University of Paris XI, Kremlin-Bicêtre (1988)
  • Specialty in Gastroenterology (1988)
  • University Degree in Oncology, Gustave Roussy / University of Paris XI (1988)
  • Master’s Degree in Biological Sciences (Statistical Methodology, Clinical Research Statistics, Immunology)
  • DEA in Epidemiology, University of Burgundy (1994)
  • PhD, Sciences of Life and Health, University of Burgundy (1998)

Areas of Clinical & Research Expertise

  • Pancreatic adenocarcinoma
  • Metastatic colorectal cancer
  • Hepatocellular carcinoma
  • Biliary tract cancers
  • Neuroendocrine tumors
  • Hepatic arterial infusion chemotherapy
  • Biomarker-driven oncology
  • Phase II–III international clinical trials

Clinical Research Leadership

  • Participation in more than 300 clinical trials over the past 25 years
  • Principal Investigator of more than 80 clinical trials during the last 15 years

Publications & Academic Impact

The author has contributed extensively to the scientific literature, with 583 peer-reviewed publications indexed in PubMed. Their scholarly impact is reflected in a h-index of 98 according to Web of Science (September 2025) and an even higher h-index of 128 based on Google Scholar (September 2025), highlighting the broad citation and influence of their research across the global scientific community.

Recent publications (2019–2025) include major contributions in journals such as:

  • The Lancet Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • ESMO Open

His work spans systemic therapy innovations, immunotherapy combinations, molecular profiling, and precision medicine in gastrointestinal oncology.

Professional Memberships & Leadership Roles

  • Member, European Society for Medical Oncology (since 1996)
  • French National Representative (2011–2016)
  • Member, Clinical Guidelines Committee (since 2020)
  • Co-Chair, WCGIC–ESMO GI Congress (2020–2023)
  • Co-Chair, ESMO GI Congress (since 2024)
  • Member, European Organisation for Research and Treatment of Cancer (GI Group since 1995)
  • Secretary (2007–2014)
  • Chair (2015–2017)
  • Member, French Society of Gastroenterology (since 1990)
  • Member, French Society of Cancer (since 1995)
  • Chair, Clinical Trials Committee, WIN Consortium (October 2022 – December 2023)